H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)’s PKP2 Program

TheFly reported connected January 13 that H.C. Wainwright expert Mitchell Kapoor lowered the terms people for LXEO to $10 from $13 and maintained a Buy rating. The steadfast believes that the marketplace is inactive not persuaded by LXEO’s caller PKP2 findings; the driblet implies a lesser anticipation of acceptance for the PKP2 program.

A time earlier, connected January 12, Lexeo Therapeutics, Inc. (NASDAQ:LXEO) released preliminary results from its HEROIC-PKP2 Phase I/II proceedings of LX2020, which is an AAV-based cistron therapy for PKP2-associated arrhythmogenic cardiomyopathy. There was nary clinically important complement activation, and LX2020 was usually good tolerated crossed dosage cohorts. PKP2 macromolecule accrued successful a dose-dependent mode during treatment, averaging 93% successful the low-dose radical and 162% successful the high-dose group. Premature ventricular contractions and non-sustained ventricular tachycardia are examples of arrhythmia features that often amended oregon stabilize.

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is simply a clinical‑stage familial medicine institution focused connected processing innovative cistron and RNA therapies to people the underlying causes of cardiovascular diseases. It advances candidates for conditions similar Friedreich’s ataxia and arrhythmogenic cardiomyopathy to amended long‑term bosom wellness outcomes.

While we admit the imaginable of LXEO arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.